XOMA, Ltd. (NASDAQ: XOMA) is focused on the discovery and development of antibodies, one of the most powerful and transformative fields of drug innovation today. By building on its pioneering proprietary pipeline, antibody discovery and development platform, and multiple revenue streams, the company is creating novel human antibody therapeutics that could revolutionize medicine and reshape people’s lives. For further information, visit the Company’s web site at www.xoma.com.
- 17 years ago
QualityStocks
XOMA, Ltd. (NASDAQ: XOMA)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – VolitionRx (NYSE American: VNRX) Prepares Reimbursement Submission for Nu.Q Cancer Assays in France
VolitionRx Ltd. (NYSE American: VNRX) (“Volition”), a multi-national epigenetics company, announced that it is preparing a reimbursement submission for its Nu.Q®…
-
QualityStocksNewsBreaks – Brand Engagement Network Inc. (NASDAQ: BNAI) Reports Warrant Exercises, Debt Conversion, and Public Warrants Update
Brand Engagement Network Inc. (NASDAQ: BNAI) announced on Wednesday that it generated approximately $1.46 million…
-
Soligenix (NASDAQ: SNGX) Positioning for Impact in Growing Rare-Disease Landscape
The World Health Organization’s recent recognition of rare diseases as a global health priority underscores…